Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFINITOR vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women in combination with exemestane after failure of letrozole or anastrozole,Progressive neuroendocrine tumors of pancreatic origin (PNET) in unresectable, locally advanced or metastatic disease,Advanced renal cell carcinoma (RCC) after failure of sunitinib or sorafenib,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients requiring therapeutic intervention but not amenable to curative resection
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life: 30 hours (range 15–40 hours) in healthy subjects; increases to 40–70 hours in moderate hepatic impairment.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Substrate of CYP3A4; metabolized primarily by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily fecal (80%) and renal (5%) as unchanged drug and metabolites. Biliary excretion is significant.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
74% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Approximately 85-90% bound to serum albumin.
Mean steady-state Vd: 342 L (approx. 4.9 L/kg in a 70 kg adult), indicating extensive tissue distribution.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability: approximately 16% (low due to P-glycoprotein efflux and first-pass metabolism); food reduces variability but does not alter AUC significantly.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment for mild to moderate renal impairment (Cr Cl >=30 m L/min). For severe renal impairment (Cr Cl <30 m L/min): reduce dose to 5 mg once daily. End-stage renal disease (Cr Cl <15 m L/min): use with caution, no specific recommendation.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg daily; Child-Pugh C: reduce dose to 2.5 mg daily, or consider alternate therapy.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For SEGA: 5 mg/m^2 orally once daily, adjusted to achieve everolimus trough concentrations of 5-15 ng/m L. Dose adjustments per AUC or tolerability. Not approved for other indications in children.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; start at recommended adult dose. Monitor for increased risk of infections, stomatitis, and metabolic effects due to age-related decline in organ function.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
No black box warnings.
None.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions including anaphylaxis,Angioedema,Renal failure,Impaired wound healing,Metabolic effects (hyperglycemia, dyslipidemia),Myelosuppression,Immunosuppression leading to increased risk of infections,Cases of fatal hemorrhage in patients with history of bleeding,Radiation sensitization and recall reactions, especially in patients with previous radiation therapy,Increased risk of pneumocystis jirovecii pneumonia (PJP) and other opportunistic infections; consider prophylaxis,Avoid live vaccines
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) due to CYP3A4 inhibition increasing everolimus levels. Take consistently with or without food, but high-fat meals reduce absorption. Avoid St. John's wort.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (m TOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxic. First trimester exposure carries risk of structural anomalies; second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use only if benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Breastfeeding is not recommended due to potential adverse effects on the developing immune system and growth.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce drug exposure; however, given the teratogenic risk, use during pregnancy should be avoided. If unavoidable, consider therapeutic drug monitoring if available and adjust dose to achieve target trough concentrations (typically 3-8 ng/m L for transplant indications; for oncology, refer to specific protocol).
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Monitor renal function and blood glucose regularly; Afinitor (everolimus) can cause non-infectious pneumonitis, so obtain baseline chest imaging and assess for new or worsening respiratory symptoms. Adjust dose for moderate hepatic impairment (Child-Pugh B). Avoid live vaccines during treatment.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take Afinitor at the same time each day, consistently either with or without food.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening cough, chest pain, or difficulty breathing immediately.,Monitor for signs of infection such as fever, chills, or sore throat; avoid large crowds and sick individuals.,Use effective contraception during treatment and for 8 weeks after stopping.,Do not crush or chew tablets; swallow whole with a glass of water.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFINITOR vs AURLUMYN, answered by our medical review team.
AFINITOR is a mTOR Inhibitor Antineoplastic that works by Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFINITOR and AURLUMYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFINITOR is: 10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFINITOR and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFINITOR is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (mTOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxi. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.